- Skye Bioscience (SKYE, Financial) partners with Arecor Therapeutics to develop an enhanced formulation of obesity drug nimacimab using Arestat™ technology.
- Nimacimab exhibits a best-in-class half-life of 18-21 days, surpassing GLP-1-based therapies, with once-weekly dosing.
- Phase 2a trial results for nimacimab expected by late Q3 or early Q4 2025.
Skye Bioscience, Inc. (SKYE) has announced a partnership with Arecor Therapeutics plc to enhance the formulation of its obesity drug candidate, nimacimab, through Arecor's Arestat™ formulation technology platform. This collaboration aims at developing a higher concentration formulation that could lead to smaller injection volumes and enhanced patient compliance. Skye will fund the development and retains the option to license the rights for further commercialization.
Nimacimab, a novel CB1-inhibiting monoclonal antibody, is currently in Phase 2a CBeyond™ clinical trials, with data anticipated by late Q3 or early Q4 2025. The drug demonstrates a best-in-class half-life of 18-21 days, allowing for once-weekly dosing, a significant advantage over current GLP-1 receptor agonist therapies.
Through this collaboration, Skye aims to address key market challenges such as patient adherence and tolerability, crucial factors for obesity medications. Importantly, nimacimab does not exhibit the neuropsychiatric toxicity concerns linked with small-molecule CB1 inhibitors, marking it as a potentially safer alternative to existing weight loss treatments.
The strategic timing of this partnership aligns with Skye’s ongoing clinical trials, facilitating the simultaneous progression of both clinical and formulation developments. This ensures that any optimized version of nimacimab can swiftly advance into subsequent trial phases without significant delays.
